



# HHS Public Access

Author manuscript

*Hematol Oncol Clin North Am.* Author manuscript; available in PMC 2022 April 01.

Published in final edited form as:

*Hematol Oncol Clin North Am.* 2021 April ; 35(2): 205–216. doi:10.1016/j.hoc.2020.11.003.

## The Microenvironment in Myeloproliferative Neoplasms

**Angela G Fleischman, M.D, PhD,**

Division of Hematology/Oncology, Department of Medicine, Department of Biological, Chemistry, Irvine Chao Family Comprehensive Cancer Center, University of California, 839 Health Sciences Rd, Sprague Hall 126, Irvine, CA 92617

**Gajalakshmi Ramanathan, PhD**

Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, CA

### Keywords

Inflammation; microenvironment; cytokines; myeloproliferative neoplasm; prognosis; myeloid cells

### Introduction

Myeloproliferative neoplasms (MPN) are a classic example of a group of diseases in which inflammation and the neoplastic clone are so intimately entwined it is difficult to ascertain which is the “chicken” and which is the “egg”. Myeloproliferative neoplasms are typified by a chronic inflammatory milieu that provides a permissive microenvironment for disease progression and severity. Inflammatory signaling involving the malignant and non-malignant cells contribute to the MPN symptom burden, thrombotic risk and disease evolution and transformation to acute myeloid leukemia. Chronic inflammation is characterized by elevated levels of circulating inflammatory cytokines and chemokines while inflammatory cells and soluble mediators of inflammation constitute the inflammatory microenvironment in the MPNs. In addition to the presence of MPN driver mutations, disease heterogeneity suggests that host factors likely shape the pathologic consequences of the presence of the MPN neoplastic clone.

Plasma/serum measurements of various cytokines and other soluble proteins reflect inflammatory processes and could serve as noninvasive diagnostic or prognostic tools for predicting disease evolution in patients with MPNS<sup>1</sup>. Considerable progress has been made on better understanding the genetic basis of the MPNs since the discovery of major driver somatic mutations in Janus kinase 2 (*JAK2*)<sup>2–5</sup>, calreticulin (*CALR*)<sup>6,7</sup> and myeloproliferative leukemia virus oncogene (*MPL*)<sup>8–10</sup>. Despite this, mutation targeted, and selective MPN therapies have been slow to exploit this knowledge and remain challenging. One reason for this is significant disease heterogeneity due to the effect of an altered

corresponding author: agf@hs.uci.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

microenvironment on disease pathogenesis. Thus, applying broader approaches towards identifying novel biomarkers for disease monitoring and combined therapies will hopefully lead to better outcomes.

This review will discuss the role of an inflammatory microenvironment as a driver of clonal evolution in the MPNs, cytokine production in the MPNs, use of inflammatory cytokines as diagnostic and prognostic tools, and the use of the inflammatory microenvironment as a therapeutic targets.

## Chronic inflammation as a contributor to the development of MPNs

There is evidence supporting the notion that chronic inflammation precedes the development of MPNs, thus creating a permissive environment for the expansion of the mutant MPN driver clone. A prior history of an autoimmune disease is associated with an increased risk of developing an MPN (Odds Ratio (OR)=1.2)<sup>11</sup>. A history of inflammation mediated by an infection has also been associated with an increased risk of myeloid malignancies, however only a history of cellulitis was associated with a significantly increased risk of an MPN (OR 1.34)<sup>12</sup>. Modifiable lifestyle factors that lead to chronic inflammation may also play a role in the development of MPNs. For example, smoking increases the risk of MPNs<sup>13, 14</sup>. Obesity has been associated with an increased risk for multiple malignancies, including MPNs<sup>14–16</sup>. This suggests that aggressive treatment of autoimmune and inflammatory conditions and lifestyle modifications aimed at reducing inflammation may be impactful to reduce one's risk of developing an MPN.

Non-modifiable factors such as the patient's germline predisposition also likely contribute to the development of an MPN. Although MPN driver mutations are clearly not inheritable, the predisposition to develop a somatic MPN driver mutation is. Interestingly, first-degree relatives of MPN patients have a 4–5-fold higher risk of developing an MPN<sup>17</sup>. Among the Single Nucleotide Polymorphisms (SNPs) identified as being associated with MPN include inflammasome-related genes<sup>18</sup> and monocyte chemoattractant protein-1 (MCP-1)<sup>19</sup>, suggesting that the host's immune milieu may contribute to the genetic predisposition to acquire an MPN.

## MPN subtype specific cytokine signatures

Although MPN subtypes can share identical driver mutations such as *JAK2*<sup>V617F</sup> the resulting phenotype is variable. Just like other clinical MPN subtype specific clinical features, there appears to be subtype specific cytokine signatures. A recent longitudinal study of more than 400 patients<sup>20</sup> identified specific inflammatory cytokine signatures according to disease subtypes. Ten cytokines including interferon gamma (INF- $\gamma$ ), interleukin-1 receptor antagonist (IL-1RA), IL-6, IL-8, IFN- $\gamma$ -inducible protein 10 (IP-10), epidermal growth factor (EGF), eotaxin (CCL11), tumor necrosis factor-alpha (TNF- $\alpha$ ), transforming growth factor-alpha (TGF- $\alpha$ ), and growth-regulated oncogene (GRO- $\alpha$  or CXCL1) were significantly altered and showed strong disease subtype specificity. (Figure 1) Specifically, primary myelofibrosis (PMF) was associated with increased levels of TNF-

$\alpha$ , IP-10, and IL-8 while TGF- $\alpha$  was unique to polycythemia vera (PV) and essential thrombocythemia (ET) presented with higher eotaxin, EGF and GRO- $\alpha$  levels<sup>20</sup>.

Another study measured plasma cytokine levels in patients with MPN, younger than 35 years, to identify possible subtype-specific biomarkers. Dickkopf-related protein 1 (Dkk-1) was found to be the most significantly increased protein in patients with MPN compared with healthy donors.<sup>21</sup> Plasma Dkk-1 levels normalized to platelet counts were not significantly different between controls and ET but could discriminate ET from pre-PMF, in both JAK2<sup>V617F</sup> and CALR mutant patients (Fig. 2).

The patients with PV exhibit an altered cytokine milieu with significantly higher levels of IL-1RA, IL-5, IL-6, IL-7, IL-8, IL-12, IL-13, IFN- $\gamma$ , granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein-1alpha (MIP-1 $\alpha$ ), MIP-1 $\beta$ , hepatocyte growth factor (HGF), IP-10, monokine induced by IFN-gamma (MIG), MCP-1, and vascular endothelial growth factor (VEGF) compared with normal controls.<sup>22</sup> A comparative study of plasma cytokine profiles in PV and ET MPN sub-types showed differentially elevated levels of IL-4, IL-8, GM-CSF, IFN- $\gamma$ , MCP-1, platelet-derived growth factor (PDGF), and VEGF in ET as compared with PV.<sup>23</sup>

High levels of serum IL-8, IL-11, leptin, HGF and MCP-1 has been reported in PV<sup>24, 25</sup> and IL-11 and HGF levels were correlated with neutrophil counts and hematocrit levels in PV patients<sup>25</sup>. Also, while IL-10 and IL-22 were increased in both PV and ET patients compared to controls, IL-23 was selectively elevated only in PV<sup>26</sup>.

Global cytokine analyses utilizing human cytokine arrays showed increased TIMP-1, MIP-1 $\beta$  and insulin-like growth factor binding factor-2 (IGFBP-2) in PMF patients but not ET or PV<sup>27</sup>. Serum IL-17 was also exclusively elevated in PMF patients compared to healthy controls but not in PV or ET patients<sup>28</sup>. IL-17 is a marker of angiogenic activity and is thought to enhance angiogenesis in the pre-fibrotic stage of PMF<sup>28</sup>.

In treatment naïve patients, elevated cytokine profiles of GM-CSF, IL-1 $\beta$ , IL-4, IL-5, IL-6, IL-10, IFN- $\alpha$ 2, MIP-1 $\alpha$ , IL-12, and TNF- $\alpha$  were observed in all three MPN categories as compared to age-matched control subjects<sup>29</sup>. MPN subset analysis also revealed intra-disease variations with PMF displaying additional cytokine modulations such as increased IL-17A compared to controls, higher levels of IFN- $\gamma$ , IL-12, IL-17A and IP-10 in comparison to ET patients and elevated plasma levels of IL-12, IL-4 and GM-CSF compared to PV patients<sup>29</sup>. JAK2<sup>V617F</sup> mutational status was also associated with higher IP-10 levels in myelofibrosis. Subsequently, although all MPN patients displayed an inflammatory status, PMF emerged as the highest producer of cytokines and chemokines<sup>29</sup>.

### Association of cytokines with specific disease outcomes

Specific cytokines are associated specific disease outcomes, suggesting that cytokine profiling could be useful clinically as predictive tools. A study involving 127 PMF patients showed increased IL-1 $\beta$ , IL-1RA, IL-2R, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, TNF- $\alpha$ , granulocyte colony-stimulating factor (G-CSF), IFN- $\alpha$ , MIP-1 $\alpha$ , MIP-1 $\beta$ , HGF, IP-10, MIG, MCP-1 and VEGF levels as well as decreased IFN- $\gamma$  levels compared to normal

controls. Treatment naïve PMF subjects displayed increased levels of IL-8, IL-2R, IL-12, IL-15, and IP-10 which predicted inferior survival. Association of phenotypic clinical features with cytokines included IL-8 with constitutional symptoms, leukocytosis and leukemia free survival, IL-2R and IL-12 with transfusion need, IP-10 correlated with thrombocytopenia while HGF, MIG and IL-1RA corresponded with marked splenomegaly<sup>30</sup>.

Vaidya et al assessed the disease phenotypic and prognostic relevance of cytokine levels in PV and found that IL-12 levels correlated with hematocrit levels, IL-1 $\beta$  with leukocytosis and IFN $\alpha$ /IFN $\gamma$  with thrombocytosis. MIP-1 $\beta$ , was significantly associated with an inferior overall survival<sup>22</sup>. A recent study found that high levels of GRO- $\alpha$  was associated with an increased risk of transformation of ET to MF. Additionally, longitudinal sampling indicated decreasing EGF levels in ET patients strongly correlated with disease transformation risk<sup>20</sup>.

Bourantas et al., demonstrated increased serum beta-2-microglobulin, IL-2 and soluble IL-2 receptor alpha (sIL-2RA) in with MPNs patient progressing to advanced clinical stages<sup>31</sup>. Panteli et al., observed that serum levels of IL-2, sIL-2RA and IL-6 were increased when PMF progressed to MPN-blast phase (MPN-BP) and positively correlated with bone marrow angiogenesis, hence indicating that disease progression is coupled with amplified inflammation and that cytokine levels can be useful biomarkers to predict disease progression such as bone marrow angiogenesis<sup>32</sup>.

Thus, measuring cytokines could potentially be leveraged as a tool for disease monitoring and to provide parallel information in addition to genomic and clinical data to predict disease progression/transformation.

## Cellular components of inflammation in MPN

Emerging evidence indicates that inflammation in the bone marrow (BM) microenvironment and systemic inflammation contribute to the development and progression of MPNs. Different cell types act as mediators of inflammation in MPNs including mutant and normal hematopoietic stem and progenitor cells, mesenchymal stromal cells, megakaryocytes, monocytes, platelets, and endothelial cells. These cells produce numerous inflammatory cytokines that act in an autocrine and paracrine fashion to provide a self-perpetuating and permissive microenvironment for disease evolution ultimately resulting in bone marrow fibrosis and transformation to MPN-BP.

### Bone marrow hematopoietic cells

The effect of MPN driver mutations on inflammatory transcriptional programs and cytokine secretion in hematopoietic stem and progenitor cells (HSPCs) can lead to an inflammatory bone marrow niche that supports the proliferation of mutant cells. We observed increased circulating TNF- $\alpha$  in MPN patients in comparison to healthy controls and also demonstrated that mononuclear cells and CD34+ cells from *JAK2*<sup>V617F</sup> MPN patients unlike normal controls are resistant to the growth suppressive effects of TNF- $\alpha$  while colony formation.<sup>33</sup> Thus, the presence of *JAK2*<sup>V617F</sup> not only increases TNF- $\alpha$  secretion but also creates a favorable environment for MPN mutant cell expansion<sup>33</sup>. Similarly, Lipocalin-2 is another

molecule that has been shown to be increased in the serum and conditioned media of bone marrow mononuclear cells from MPN patients compared to controls<sup>34</sup>. The presence of lipocalin-2 also reduced the proliferation and colony-forming capacity of bone marrow CD34<sup>+</sup> cells from non-MPN patients or normal controls but not MPN patients thus providing a relative growth advantage to MPN clones<sup>34, 35</sup>. Lipocalin was expressed by myelofibrosis marrow myeloid cells and not erythroid or megakaryocytic cells<sup>35</sup>. Bone marrow neural death has been associated with IL-1 $\beta$  released from mutant HSCs reduced mesenchymal stromal cells and allowed the uncontrolled expansion of mutant HSCs and disease progression<sup>36</sup>.

Using single-cell technology to understand disease pathology in myelofibrosis, Psaila et al., identified a megakaryocyte differentiation bias in early human multipotent stem cells and strong expression of fibrotic mediators in megakaryocyte progenitors<sup>37</sup>. Furthermore, cell surface expression of G6B was specific to mutant HSPCs from myelofibrosis patients thus identifying a potential selective target for MF HSPCs<sup>37</sup>. CD34<sup>+</sup> cells from patients with *CALR*-mutations were profiled by integrating target genotyping with single-cell RNA sequencing. This technology revealed that the frequency of *CALR*-mutated cells was higher in committed myeloid progenitors and megakaryocyte progenitors indicating increased fitness of the *CALR* mutation with myeloid differentiation. Compared to wild-type HSPCs, an upregulation of NF- $\kappa$ B pathway genes in undifferentiated mutant HSCs supports a cell-intrinsic role for *CALR* mutation in NF- $\kappa$ B activation<sup>38</sup>.

Megakaryocytes in PMF possess an inflammatory and pro-fibrotic secretome that is a major driver of BM fibrosis<sup>39</sup>. The role of megakaryocytes in promoting inflammation has been reviewed separately in this edition and will not be discussed here.

### Mesenchymal stromal cells

BM mesenchymal stromal cells (also mesenchymal stem cells or multipotent stromal cells (MSCs)) contribute to the maintenance of HSCs and normal hematopoiesis. Leukemic myeloid cells remodel the bone marrow niche into a “self-reinforcing leukemic niche” that favorably supports leukemic stem cells but not healthy stem cells<sup>40</sup>. Nestin-positive MSC reduction was observed in the bone marrow of MPN patients and MPN mouse models carrying the human *JAK2*<sup>V617F</sup> mutation due to IL-1 $\beta$  released by mutant HSCs resulting in a favorable environment for mutant HSC expansion<sup>36</sup>.

MSCs from PMF patients are characterized by an increased secretion of TGFB, BMP and glycosaminoglycans and specific impairment of osteogenic abilities. Transcriptome analysis identified a TGF- $\beta$  signature in primary MF MSCs<sup>41</sup>. Differentiation of glioma associated oncogene positive (Gli1<sup>+</sup>) MSCs towards fibrosis driving myofibroblasts was shown in mouse models of myelofibrosis. Similarly, BM samples from MPN patients also showed an increased frequency of Gli1<sup>+</sup> cells and corresponded to the severity of fibrosis by reticulin staining irrespective of *JAK2*<sup>V617F</sup> or *CALR* mutation status<sup>42</sup>. Leptin receptor (*Lepr*) expressing MSCs were also found to be expanded and fibrogenic in a mouse model of myelofibrosis<sup>43</sup>.

## Monocytes

Mature hematopoietic cells in the peripheral blood are pivotal sources of increased systemic cytokines in MPN. Classical CD14+CD16- monocytes are a strongest producers of cytokines including TNF- $\alpha$ , IL-6, IL-8 and IL-10 in MF<sup>44</sup>. TNF- $\alpha$  is consistently increased in all MPN subtypes and has an integral role in the clonal expansion of *JAK2*<sup>V617F</sup> cells<sup>33</sup>. We recently showed that primary monocytes from MPN patients have extensive TNF- $\alpha$  production compared to normal controls in response to stimulation due to a dampened response to the anti-inflammatory cytokine, IL-10<sup>45</sup>. IL-10 receptor (IL-10R) signaling via suppressor of cytokine signaling-3 (SOCS3) was found to be downregulated in MPN patients. Interestingly, persistent TNF- $\alpha$  production was observed in both unmutated and *JAK2*<sup>V617F</sup> monocytes indicating a non-cell autonomous role for monocytes in MPN inflammation<sup>45</sup>. Very recently, CD56+CD14+ pro-inflammatory monocytes have been identified as a pivotal source of GRO- $\alpha$  in ET patients thus creating an environment suitable for MPN disease evolution<sup>20</sup>.

## Granulocytes

Single cell-cytokine profiling of circulating granulocytes from PMF patients showed that several cytokines including IL-6, IL-8, IL-10, IL-12, TNF- $\alpha$ , CCL2, CCL3 and CCL5, were significantly increased compared to healthy controls<sup>46</sup>. This was the result of an increased fraction of cytokine secreting cells and the level of individual cytokines per cell. The proportion of cytokine secreting myeloid cells was higher than the *JAK2*<sup>V617F</sup>-mutant allele burden, which suggested that non-malignant cells also contribute to cytokine production. Thus, aberrant inflammatory signaling in MPN is not restricted to cell-intrinsic effects but also non-cell autonomous processes<sup>46</sup>.

The formation of neutrophil extracellular traps by neutrophils not only contributes to innate immunity and host defense but also promotes thrombosis<sup>47</sup>. Increased neutrophil activation has been reported in ET and PV with increased cell surface CD11b expression and circulating myeloperoxidase levels<sup>48</sup>. Recently, Wolach et al., demonstrated that neutrophils from MPN patients show increased NET formation with a pro-thrombotic phenotype which can be blocked by ruxolitinib<sup>49</sup>. Increased NET formation was associated with PAD4 overexpression in *JAK2*<sup>V617F</sup> PV patient samples<sup>49</sup>. Thus, premature neutrophil activation in MPN is a cell-intrinsic effect of the *JAK2*<sup>V617F</sup> mutation and is associated with thrombotic events. We also demonstrated that N-acetylcysteine (NAC) reduces NET formation in MPN patients and could be used a potential anti-thrombotic in MPN<sup>50</sup>.

## Platelets

Platelets play a role in innate immunity and inflammation in addition to their hemostatic function and contribute to thrombo-inflammation in MPN<sup>51</sup>. Thrombosis is a major cause of mortality and morbidity in MPN patients with several underlying mechanisms including membrane alterations on red blood cells, activated platelets, activated leukocytes, platelet-leukocyte aggregates, and dysfunctional endothelium. Systemic inflammation also plays a critical role in the development of vascular events as elevated high sensitivity C-reactive protein (hsCRP) is significantly associated with thrombosis risk in PV and ET patients<sup>52</sup>.



Platelet interactions with neutrophils and monocytes in MPN triggers activation of both cell types and stimulates inflammatory and thrombotic processes. We and others have reported increased platelet-leukocyte aggregates in MPN patients<sup>50, 53</sup>. We also observed that MPN platelets can induce NET formation with normal and MPN neutrophils without an external stimulus indicating that MPN platelets generate a prothrombotic microenvironment<sup>50</sup>. Platelet crosstalk with monocytes can also increase cytokine synthesis and release since monocytes are already known to play an important role in MPN inflammation<sup>44, 45</sup>. Inflammatory cytokines and reactive oxygen species result in an activated and pro-thrombotic endothelium as observed by increased von Willebrand factor (vWF) and E-selectin levels<sup>54</sup>. Recruitment of platelets and leukocytes to an activated endothelium results in a prothrombotic phenotype in MPN patients. Activated platelets themselves can act as immune cells by releasing pro-inflammatory cytokines such as CCL5 and platelet factor 4 (PF4 or CXCL4) stored in  $\alpha$ -granules<sup>55</sup>. Elevated cytokine levels lead to reciprocal activation of platelets thus driving the thrombo-inflammatory loop in MPN.

### **Looking ahead – how could we incorporate knowledge of the microenvironment to aid in the clinical care of MPN patients?**

Although our knowledge of the role of inflammation in MPN patients is rapidly expanding, we have yet to fully harness this knowledge toward improvements in diagnosis, prognostication, monitoring of disease progression or treatment, and use as a therapeutic target.

Cytokine profiling remains relatively untapped as a clinical tool. MPN subtypes appear to have unique cytokine profile signatures (see above), and it is conceivable that sometime in the future cytokine profiling could be incorporated as a diagnostic tool to aid in delineating the MPN subtype. Moreover, cytokine profiling could also possibly increase the accuracy of our prognostic scoring tools in MPN. Not only could cytokines be leveraged to help predict general prognosis but may be most helpful to identify patients at highest risk of specific outcomes such as thrombosis. Moreover, cytokines could also possibly be utilized to help aid in selection of drugs, for example those who are most likely to benefit from JAK 1/2 inhibitors.

Targeting of specific microenvironmental offender cell types could be applied therapeutically in MPNs. An example of targeting specific microenvironmental cell subtypes involved in fibrosis is the drug PRM-151, which targets the differentiation of fibrocytes, a cell type important for fibrosis<sup>56</sup>. There are a multitude of other potential targets, including Gli1 proteins on MSCs by GANT61<sup>42</sup>, G6B on mutant HSCs<sup>37</sup>, PDGFRA signaling pathway in fibrosis<sup>43</sup>, and reducing NETs and platelet-leukocyte aggregates<sup>50</sup>. A greater understanding of the intricate relationship between inflammation and MPN disease pathogenesis will allow for more accurate therapeutic targeting to achieve the much-desired goal of disease modifying therapy in MPN.

## Acknowledgments

**Financial Support:** This research was supported by funds from the Tobacco-Related Disease Research Program of the University of California, Grant Numbers T29FT0267 (G.R) and T29IP0414 (A.G.F). G.R was supported by the NCI T32CA009054.

**Disclosures:** The authors declare that they have no conflict of interests. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number T32CA009054. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

## References

1. Reikvam H, Fredly H, Kittang AO, Bruserud O. The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. *Toxins (Basel)*. Feb 2013;5(2):336–62. doi:10.3390/toxins5020336 [PubMed: 23430540]
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. Apr 2005;7(4):387–97. doi:10.1016/j.ccr.2005.03.023 [PubMed: 15837627]
3. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. Apr 2005;434(7037):1144–8. doi:10.1038/nature03546 [PubMed: 15793561]
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med*. Apr 2005;352(17):1779–90. doi:10.1056/NEJMoa051113 [PubMed: 15858187]
5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*. 2005 Mar 19–25 2005;365(9464):1054–61. doi:10.1016/S0140-6736(05)71142-9 [PubMed: 15781101]
6. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *N Engl J Med*. Dec 2013;369(25):2391–2405. doi:10.1056/NEJMoa1312542 [PubMed: 24325359]
7. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med*. Dec 2013;369(25):2379–90. doi:10.1056/NEJMoa1311347 [PubMed: 24325356]
8. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. *PLoS Med*. Jul 2006;3(7):e270. doi:10.1371/journal.pmed.0030270 [PubMed: 16834459]
9. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. *Blood*. Nov 2006;108(10):3472–6. doi:10.1182/blood-2006-04-018879 [PubMed: 16868251]
10. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. *Blood*. Jul 2008;112(1):141–9. doi:10.1182/blood-2008-01-131664 [PubMed: 18451306]
11. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. *Haematologica*. Jul 2010;95(7):1216–20. doi:10.3324/haematol.2009.020412 [PubMed: 20053870]
12. Titmarsh GJ, McMullin MF, McShane CM, Clarke M, Engels EA, Anderson LA. Community-acquired infections and their association with myeloid malignancies. *Cancer Epidemiol*. Feb 2014;38(1):56–61. doi:10.1016/j.canep.2013.10.009 [PubMed: 24275260]
13. Pedersen KM, Bak M, Sørensen AL, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study. *Cancer Med*. 11 2018;7(11):5796–5802. doi:10.1002/cam4.1815 [PubMed: 30318865]



14. Duncombe AS, Anderson LA, James G, et al. Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms. *Hemasphere*. Feb 2020;4(1):e327. doi:10.1097/HS9.0000000000000327 [PubMed: 32072143]
15. Murphy F, Kroll ME, Pirie K, Reeves G, Green J, Beral V. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. *Br J Cancer*. Jun 2013;108(11):2390–8. doi:10.1038/bjc.2013.159 [PubMed: 23640394]
16. Leal AD, Thompson CA, Wang AH, et al. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. *Int J Cancer*. Apr 2014;134(7):1741–50. doi:10.1002/ijc.28492 [PubMed: 24114627]
17. Sud A, Chattopadhyay S, Thomsen H, et al. Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. *Blood*. 08 2018;132(9):973–976. doi:10.1182/blood-2018-06-858597 [PubMed: 29991558]
18. Huang Y, Wang H, Hao Y, et al. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. *Nat Cell Biol*. 06 2020;22(6):716–727. doi:10.1038/s41556-020-0510-3 [PubMed: 32367047]
19. Masselli E, Carubbi C, Cambò B, et al. The –2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. *Leukemia*. 10 2018;32(10):2266–2270. doi:10.1038/s41375-018-0088-y [PubMed: 29568096]
20. Øbro NF, Grinfeld J, Belmonte M, et al. Longitudinal Cytokine Profiling Identifies GRO- $\alpha$  and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia. *Hemasphere*. Jun 2020;4(3):e371. doi:10.1097/HS9.0000000000000371 [PubMed: 32647796]
21. Mambet C, Necula L, Mihai S, et al. Increased Dkk-1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms. *J Cell Mol Med*. Jul 2018;doi:10.1111/jcmm.13753
22. Vaidya R, Gangat N, Jimma T, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. *Am J Hematol*. Nov 2012;87(11):1003–5. doi:10.1002/ajh.23295 [PubMed: 22965887]
23. Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. *Exp Hematol*. May 2014;42(5):360–8. doi:10.1016/j.exphem.2014.01.006 [PubMed: 24463275]
24. Hermouet S, Godard A, Pineau D, et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. *Cytokine*. Nov 2002;20(4):178–83. doi:10.1006/cyto.2002.1994 [PubMed: 12543083]
25. Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F. *Oncogene*. Feb 2011;30(8):990–1001. doi:10.1038/onc.2010.479 [PubMed: 21042281]
26. Gangemi S, Allegra A, Pace E, et al. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia. *Cell Immunol*. 2012 Jul-Aug 2012;278(1–2):91–4. doi:10.1016/j.cellimm.2012.07.003 [PubMed: 23121980]
27. Ho CL, Lasho TL, Butterfield JH, Tefferi A. Global cytokine analysis in myeloproliferative disorders. *Leuk Res*. Oct 2007;31(10):1389–92. doi:10.1016/j.leukres.2006.12.024 [PubMed: 17328948]
28. Allegra A, Alonci A, Bellomo G, et al. Evaluation of interleukin-17 serum levels in patients with chronic myeloproliferative diseases. *Tumori*. 2009 May-Jun 2009;95(3):404–5. [PubMed: 19688988]
29. Cacemiro MDC, Cominal JG, Tognon R, et al. Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation. *Hematol Transfus Cell Ther*. 2018 Apr-Jun 2018;40(2):120–131. doi:10.1016/j.htct.2017.12.003 [PubMed: 30057985]
30. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. *J Clin Oncol*. Apr 2011;29(10):1356–63. doi:10.1200/JCO.2010.32.9490 [PubMed: 21300928]

31. Bourantas KL, Hatzimichael EC, Makis AC, et al. Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders. *Eur J Haematol*. Jul 1999;63(1):19–25. doi:10.1111/j.1600-0609.1999.tb01845.x [PubMed: 10414450]
32. Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. *Br J Haematol*. Sep 2005;130(5):709–15. doi:10.1111/j.1365-2141.2005.05674.x [PubMed: 16115126]
33. Fleischman AG, Aichberger KJ, Luty SB, et al. TNF $\alpha$  facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. *Blood*. Dec 2011;118(24):6392–8. doi:10.1182/blood-2011-04-348144 [PubMed: 21860020]
34. Kagoya Y, Yoshimi A, Tsuruta-Kishino T, et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. *Blood*. Nov 2014;124(19):2996–3006. doi:10.1182/blood-2014-04-570572 [PubMed: 25217696]
35. Lu M, Xia L, Liu YC, et al. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. *Blood*. Aug 2015;126(8):972–82. doi:10.1182/blood-2014-12-618595 [PubMed: 26022238]
36. Arranz L, Sánchez-Aguilera A, Martín-Pérez D, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. *Nature*. Aug 2014;512(7512):78–81. doi:10.1038/nature13383 [PubMed: 25043017]
37. Psaila B, Wang G, Rodriguez-Meira A, et al. Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets. *Mol Cell*. 05 2020;78(3):477–492.e8. doi:10.1016/j.molcel.2020.04.008 [PubMed: 32386542]
38. Nam AS, Kim KT, Chaligne R, et al. Somatic mutations and cell identity linked by Genotyping of Transcriptomes. *Nature*. 07 2019;571(7765):355–360. doi:10.1038/s41586-019-1367-0 [PubMed: 31270458]
39. Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. *Blood*. Aug 2007;110(3):986–93. doi:10.1182/blood-2006-12-064626 [PubMed: 17473062]
40. Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. *Cell Stem Cell*. Sep 2013;13(3):285–99. doi:10.1016/j.stem.2013.06.009 [PubMed: 23850243]
41. Martinaud C, Desterke C, Konopacki J, et al. Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis. *Cancer Res*. Nov 2015;75(22):4753–65. doi:10.1158/0008-5472.CAN-14-3696 [PubMed: 26404004]
42. Schneider RK, Mullally A, Dugourd A, et al. Gli1 + Mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. *Cell Stem Cell*. 06 2017;20(6):785–800.e8. doi:10.1016/j.stem.2017.03.008 [PubMed: 28457748]
43. Decker M, Martinez-Morentin L, Wang G, et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. *Nat Cell Biol*. Jun 2017;19(6):677–688. doi:10.1038/ncb3530 [PubMed: 28481328]
44. Fisher DAC, Miner CA, Engle EK, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF $\kappa$ B signaling. *Leukemia*. 08 2019;33(8):1978–1995. doi:10.1038/s41375-019-0379-y [PubMed: 30718771]
45. Lai HY, Brooks SA, Craver BM, et al. Defective negative regulation of Toll-like receptor signaling leads to excessive TNF- $\alpha$  in myeloproliferative neoplasm. *Blood Adv*. 01 2019;3(2):122–131. doi:10.1182/bloodadvances.2018026450 [PubMed: 30647074]
46. Kleppe M, Kwak M, Koppikar P, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. *Cancer Discov*. Mar 2015;5(3):316–31. doi:10.1158/2159-8290.CD-14-0736 [PubMed: 25572172]
47. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. *Proc Natl Acad Sci U S A*. Sep 2010;107(36):15880–5. doi:10.1073/pnas.1005743107 [PubMed: 20798043]
48. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. *Blood*. Dec 2000;96(13):4261–6. [PubMed: 11110700]

49. Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. *Sci Transl Med.* 04 2018;10(436)doi:10.1126/scitranslmed.aan8292
50. Craver BM, Ramanathan G, Hoang S, et al. N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm. *Blood Adv.* 01 2020;4(2):312–321. doi:10.1182/bloodadvances.2019000967 [PubMed: 31978215]
51. Marin Oyarzún CP, Heller PG. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms. *Front Immunol.* 2019;10:1373. doi:10.3389/fimmu.2019.01373 [PubMed: 31258539]
52. Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. *Haematologica.* Feb 2011;96(2):315–8. doi:10.3324/haematol.2010.031070 [PubMed: 21173097]
53. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. *Exp Hematol.* May 2005;33(5):523–30. doi:10.1016/j.exphem.2005.01.015 [PubMed: 15850829]
54. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. *Am J Hematol.* Feb 2009;84(2):102–8. doi:10.1002/ajh.21338 [PubMed: 19105233]
55. Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis. *Circ Res.* 01 2018;122(2):337–351. doi:10.1161/CIRCRESAHA.117.310795 [PubMed: 29348254]
56. Verstovsek S, Manshour T, Pilling D, et al. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. *J Exp Med.* 08 2016;213(9):1723–40. doi:10.1084/jem.20160283 [PubMed: 27481130]

**Synopsis:**

Chronic inflammation is a hallmark of myeloproliferative neoplasms with elevated levels of pro-inflammatory cytokines being commonly found in all three subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis and disease evolution in MPN. Although the neoplastic clone and their differentiated progeny drive the inflammatory process, they also induce ancillary cytokine secretion from non-malignant cells. Here, we describe the inflammatory milieu in MPN based on soluble factors and cellular mediators. We also discuss the prognostic value of cytokine measurements in MPN patients and potential therapeutic strategies that target the cellular players in inflammation.

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript

**Key points:**


1. The inflammatory microenvironment in MPN encompasses soluble cytokines and associated cellular players.
2. A self-sustained inflammatory loop results in a milieu that supports the clonal expansion of the neoplastic clone.
3. Cytokine profiles in MPN can be leveraged for diagnosis, disease monitoring and prognostication which will help to obtain more favorable patient outcomes.



**Figure 1.**

MPN-associated cytokines and chemokines according to subtype. Dkk-1, Dickkopf-related protein 1; EGF, epidermal growth factor; GRO- $\alpha$ , growth-regulated oncogene; HGF, hepatocyte growth factor; IFN $\alpha$ , interferon alpha; IFN $\gamma$ , interferon gamma; IL-1RA, interleukin-1 receptor antagonist; IP-10, IFN-g–inducible protein 10; MIG, monokine induced by IFN-gamma; MIP, macrophage inflammatory protein-1; TGF- $\alpha$ , transforming growth factor alpha; TNF $\alpha$ , tumor necrosis factor alpha.





**Figure 2.**

Overview of the inflammatory loop in MPNs. The neoplastic hematopoietic stem cell (HSC) clone carrying the *JAK2<sup>V617F</sup>*, *CALR*, or *MPL*, mutation secretes cytokines involved in inflammation and differentiate into malignant cells of the myeloid lineage such as megakaryocytes, monocytes, and granulocytes. Together, these cells produce a host of cytokines creating an inflammatory microenvironment which in turn results in aberrant activation and function of non-malignant cells in the bone marrow and peripheral blood. NETs, neutrophil extracellular traps; MSC, mesenchymal stromal cell; vWF, von Willebrand factor; PLAs, platelet-leukocyte aggregates.